| 21.55 0.03 (0.14%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.22 | 1-year : | 29.46 |
| Resists | First : | 21.6 | Second : | 25.22 |
| Pivot price | 21.49  |
|||
| Supports | First : | 21.44 | Second : | 21.35 |
| MAs | MA(5) : | 21.5 |
MA(20) : | 21.47 |
| MA(100) : | 16.54 |
MA(250) : | 9.2 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74.1 |
D(3) : | 64.2 |
| RSI | RSI(14): 69 | |||
| 52-week | High : | 21.6 | Low : | 2.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FUSN ] has closed below upper band by 16.6%. Bollinger Bands are 96% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.56 - 21.67 | 21.67 - 21.76 |
| Low: | 21.29 - 21.41 | 21.41 - 21.5 |
| Close: | 21.36 - 21.56 | 21.56 - 21.71 |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Tue, 04 Jun 2024
Acquisition of Fusion Pharmaceuticals Completed - PR Newswire
Fri, 31 May 2024
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement - PR Newswire
Tue, 07 May 2024
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates - PR Newswire
Wed, 20 Mar 2024
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates - PR Newswire
Tue, 19 Mar 2024
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline - Investopedia
Tue, 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 6.158e+007 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 4,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.088e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 403.7 % |
| Return on Equity (ttm) | -23.4 % |
| Qtrly Rev. Growth | 2.04e+006 % |
| Gross Profit (p.s.) | -0.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.22 |
| Dividend | 0 |
| Forward Dividend | 3.06e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|